|Bid||27.11 x 900|
|Ask||28.00 x 1300|
|Day's range||26.83 - 28.33|
|52-week range||20.60 - 99.27|
|Beta (5Y monthly)||2.31|
|PE ratio (TTM)||15.29|
|Earnings date||24 Oct 2022 - 28 Oct 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||51.00|
Bear markets are never fun. Keeping with this theme, the 2022 bear market has created a slew of attractive buying opportunities. Cosmetic surgery company InMode (NASDAQ: INMD), Swiss pharma giant Novartis (NYSE: NVS), and diabetes care behemoth DexCom (NASDAQ: DXCM) are three highly profitable companies that have been unfairly punished by this irrational market.
The popularity of cosmetic procedures is unquestionably on the rise. Major pharmaceutical AbbVie (NYSE: ABBV) is plagued by concerns about the impending patent cliff on its top-selling drug. At the same time, healthcare equipment provider InMode (NASDAQ: INMD) has been punished by Wall Street's current skepticism about growth stocks.
Shareholders of medical technology company InMode (NASDAQ: INMD) have not had a great 2022; the stock has fallen roughly 50% since the beginning of the year. Here are three reasons to consider InMode as a long-term growth stock for your portfolio. InMode designs and builds non-invasive medical equipment for cosmetic procedures like face and body contouring, hair removal, and women's wellness.